Nektar Therapeutics Equity Method Investments
Nektar Therapeutics (NKTR) had Equity Method Investments of $3.49 million as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:EquityMethodInvestments · last filed 2026-03-13
- 2025-12-31: Equity Method Investments $3.49M.
- 2025-09-30: Equity Method Investments $4.84M.
- 2025-06-30: Equity Method Investments $5.37M.
- 2025-03-31: Equity Method Investments $7.76M.
| Period end | Equity Method Investments |
|---|---|
| 2025-12-31 | $3.49M 10-K · filed 2026-03-13 |
| 2025-09-30 | $4.84M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $5.37M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $7.76M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $12.22M 10-K · filed 2026-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |